Liquidata Share/ETF/Trust Analysis
Portfolio Holdings Detail for ISIN IE00BF4RFH31
| Stock Name / Fund | iShares MSCI World Small Cap UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares III Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300PZLRJB7M8H1057 |
| ETF Ticker | WSML(USD) LSE |
| ETF Ticker | WLDS(GBP) LSE |
| ETF Ticker | IUSN(EUR) F |
| ETF Ticker | IUSN.DE(EUR) CXE |
| ETF Ticker | WLDS.LS(GBP) CXE |
| ETF Ticker | WSML.LS(USD) CXE |
| ETF Ticker | WSML.L(GBP) LSE |
| ETF Ticker | WLDS.L(GBP) LSE |
Holdings detail for ANIP
| Stock Name | ANI Pharmaceuticals Inc |
| Ticker | ANIP(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US00182C1036 |
| LEI | 5493000T6CXTND40YH31 |
Show aggregate ANIP holdings
News associated with ANIP
- HC Wainwright Forecasts Strong Price Appreciation for ANI Pharmaceuticals (NASDAQ:ANIP) Stock
- ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) had its target price increased by HC Wainwright from $93.00 to $121.00 in a report issued on Wednesday, MarketBeat Ratings reports. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 24.13% from the stock’s […] - 2025-09-19 03:05:01
- ANI Pharmaceuticals (NASDAQ:ANIP) Reaches New 12-Month High Following Analyst Upgrade
- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) hit a new 52-week high on Tuesday after Guggenheim raised their price target on the stock from $86.00 to $114.00. Guggenheim currently has a buy rating on the stock. ANI Pharmaceuticals traded as high as $96.66 and last traded at $96.30, with a volume of 66131 shares […] - 2025-09-10 02:20:55
- ANI Pharmaceuticals (NASDAQ:ANIP) COO Sells $4,618,078.50 in Stock
- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) COO Muthusamy Shanmugam sold 52,990 shares of the firm’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $87.15, for a total transaction of $4,618,078.50. Following the completion of the sale, the chief operating officer directly owned 531,920 shares […] - 2025-08-21 05:19:08
- Deutsche Bank AG Trims Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
- Deutsche Bank AG trimmed its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 6.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 218,086 shares of the specialty pharmaceutical company’s stock after selling 14,242 shares during […] - 2025-08-15 05:15:08
- ANI Pharmaceuticals (NASDAQ:ANIP) Stock Price Expected to Rise, Truist Financial Analyst Says
- ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) had its target price raised by investment analysts at Truist Financial from $65.00 to $77.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a “hold” rating on the specialty pharmaceutical company’s stock. Truist Financial’s target price suggests a potential downside of 12.84% […] - 2025-08-13 02:46:43
- Victory Capital Management Inc. Has $1.13 Million Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
- Victory Capital Management Inc. grew its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 22.4% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 16,863 shares of the specialty pharmaceutical company’s stock after buying an additional 3,086 shares during the period. Victory Capital […] - 2025-07-31 05:28:47
- Bank of New York Mellon Corp Reduces Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
- Bank of New York Mellon Corp lessened its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 3.7% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 119,262 shares of the specialty pharmaceutical company’s stock after selling 4,570 shares during the quarter. Bank of New York Mellon Corp’s holdings in ANI Pharmaceuticals […] - 2025-07-23 04:30:44
- Louisiana State Employees Retirement System Has $522,000 Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
- Louisiana State Employees Retirement System cut its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 2.5% during the first quarter, Holdings Channel.com reports. The firm owned 7,800 shares of the specialty pharmaceutical company’s stock after selling 200 shares during the quarter. Louisiana State Employees Retirement System’s holdings in ANI Pharmaceuticals were worth $522,000 […] - 2025-07-21 05:16:50
- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $78.88 Consensus Target Price from Analysts
- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) has been assigned an average recommendation of “Buy” from the nine ratings firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the […] - 2025-07-18 02:23:01
- GAMMA Investing LLC Has $95,000 Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
- GAMMA Investing LLC lifted its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 163.8% during the first quarter, Holdings Channel.com reports. The firm owned 1,419 shares of the specialty pharmaceutical company’s stock after purchasing an additional 881 shares during the period. GAMMA Investing LLC’s holdings in ANI Pharmaceuticals were worth $95,000 […] - 2025-07-07 04:17:14
- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $80.13 Average PT from Brokerages
- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) has received an average recommendation of “Buy” from the nine brokerages that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The […] - 2025-06-23 02:14:07
- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $80.13 Average Target Price from Analysts
- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) has received a consensus recommendation of “Buy” from the nine analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. […] - 2025-05-29 02:27:28
- Surprising Analyst 12-Month Target For VIOO
- Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-05-13 08:45:24
- Comerica Bank Has $1.04 Million Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
- Comerica Bank lowered its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 30.1% in the 4th quarter, HoldingsChannel reports. The firm owned 18,830 shares of the specialty pharmaceutical company’s stock after selling 8,099 shares during the period. Comerica Bank’s holdings in ANI Pharmaceuticals were worth $1,041,000 at the end of the […] - 2025-05-13 05:42:52
- MetLife Investment Management LLC Has $630,000 Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
- MetLife Investment Management LLC increased its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 6.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,397 shares of the specialty pharmaceutical company’s stock after buying an additional 675 […] - 2025-05-05 06:01:03
- Dimensional Fund Advisors LP Raises Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
- Dimensional Fund Advisors LP raised its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 4.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 685,730 shares of the specialty pharmaceutical company’s stock after purchasing an additional 30,420 […] - 2025-05-05 05:20:53
- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Recommendation of “Buy” from Analysts
- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) has been given an average rating of “Buy” by the nine analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to […] - 2025-05-01 02:12:50
- Legal & General Group Plc Acquires 2,585 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
- Legal & General Group Plc increased its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 5.6% during the fourth quarter, Holdings Channel.com reports. The fund owned 48,425 shares of the specialty pharmaceutical company’s stock after purchasing an additional 2,585 shares during the quarter. Legal & General Group Plc’s holdings in ANI […] - 2025-04-24 05:18:54
- Invesco Ltd. Lowers Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
- Invesco Ltd. lowered its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 10.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 197,545 shares of the specialty pharmaceutical company’s stock after selling 22,814 shares during the quarter. Invesco […] - 2025-04-23 05:08:58
- ANI Pharmaceuticals (NASDAQ:ANIP) Stock Price Expected to Rise, Truist Financial Analyst Says
- ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) had its target price upped by analysts at Truist Financial from $62.00 to $65.00 in a report released on Monday,Benzinga reports. The brokerage currently has a “hold” rating on the specialty pharmaceutical company’s stock. Truist Financial’s price target points to a potential downside of 5.73% from the company’s […] - 2025-04-23 02:42:48
- Vanguard Group Inc. Sells 33,739 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
- Vanguard Group Inc. reduced its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 2.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,314,372 shares of the specialty pharmaceutical company’s stock after selling 33,739 shares during the quarter. Vanguard […] - 2025-04-11 04:52:47
- ANI Pharmaceuticals (NASDAQ:ANIP) Stock Rating Lowered by StockNews.com
- ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday. Other equities analysts have also recently issued reports about the stock. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a research note on […] - 2025-04-10 03:13:02
- Brokerages Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) PT at $79.75
- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) has received a consensus rating of “Buy” from the nine brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The […] - 2025-04-09 02:04:49
- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Position Trimmed by Corebridge Financial Inc.
- Corebridge Financial Inc. reduced its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 7.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,778 shares of the specialty pharmaceutical company’s stock after selling 762 shares during the quarter. Corebridge […] - 2025-04-08 04:27:01
- Thrivent Financial for Lutherans Reduces Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
- Thrivent Financial for Lutherans trimmed its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 1.5% in the 4th quarter, HoldingsChannel reports. The firm owned 12,828 shares of the specialty pharmaceutical company’s stock after selling 200 shares during the quarter. Thrivent Financial for Lutherans’ holdings in ANI Pharmaceuticals were worth $709,000 as of its […] - 2025-04-03 04:16:46
- ANI Pharmaceuticals (NASDAQ:ANIP) Now Covered by Analysts at Jefferies Financial Group
- Jefferies Financial Group initiated coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP – Free Report) in a report released on Friday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $80.00 target price on the specialty pharmaceutical company’s stock. Several other analysts have also recently commented on ANIP. StockNews.com cut shares of ANI […] - 2025-03-17 04:26:54
- JPMorgan Chase & Co. Begins Coverage on ANI Pharmaceuticals (NASDAQ:ANIP)
- JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) in a research report issued to clients and investors on Wednesday, MarketBeat.com reports. The brokerage set an “overweight” rating and a $85.00 price target on the specialty pharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective would suggest a […] - 2025-03-14 04:34:45
- Illinois Municipal Retirement Fund Decreases Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
- Illinois Municipal Retirement Fund lowered its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 8.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 8,533 shares of the specialty pharmaceutical company’s stock after selling 799 shares during the quarter. Illinois Municipal Retirement Fund’s […] - 2025-03-05 08:46:59
- ANI Pharmaceuticals (NASDAQ:ANIP) Cut to Sell at StockNews.com
- StockNews.com downgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP – Free Report) from a hold rating to a sell rating in a report released on Monday morning. ANIP has been the subject of several other research reports. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They set an […] - 2025-03-04 04:50:49
- Brokerages Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Price Target at $77.71
- Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) have been given an average rating of “Buy” by the eight research firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy […] - 2025-02-18 04:13:03
iShares MSCI World Small Cap UCITS ETF USD (Acc) ANIP holdings
| Date | Number of ANIP Shares Held | Base Market Value of ANIP Shares | Local Market Value of ANIP Shares | Change in ANIP Shares Held | Change in ANIP Base Value | Current Price per ANIP Share Held | Previous Price per ANIP Share Held |
|---|
| 2025-10-15 (Wednesday) | 15,495 | USD 1,396,100 | USD 1,396,100 | | | | |
| 2025-10-10 (Friday) | 15,402 | USD 1,382,946 | USD 1,382,946 | | | | |
| 2025-10-08 (Wednesday) | 15,402 | USD 1,411,593 | USD 1,411,593 | | | | |
| 2025-10-07 (Tuesday) | 15,402 | USD 1,412,055 | USD 1,412,055 | 62 | USD -145 | USD 91.68 | USD 92.06 |
| 2025-10-06 (Monday) | 15,340 | USD 1,412,200 | USD 1,412,200 | 0 | USD 37,122 | USD 92.06 | USD 89.64 |
| 2025-10-03 (Friday) | 15,340 | USD 1,375,078 | USD 1,375,078 | 0 | USD 7,824 | USD 89.64 | USD 89.13 |
| 2025-10-02 (Thursday) | 15,340 | USD 1,367,254 | USD 1,367,254 | 0 | USD -16,031 | USD 89.13 | USD 90.175 |
| 2025-10-01 (Wednesday) | 15,340 | USD 1,383,285 | USD 1,383,285 | 0 | USD -21,859 | USD 90.175 | USD 91.6 |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of ANIP by Blackrock for IE00BF4RFH31
Show aggregate share trades of ANIP| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-10-07 | BUY | 62 | | | 91.680* | | 63.68 |
| 2025-09-08 | SELL | -124 | | | 95.200* | | 62.33 Profit of 7,729 on sale |
| 2025-08-15 | BUY | 62 | | | 87.470* | | 62.19 |
| 2025-08-07 | BUY | 192 | | | 69.010* | | 62.01 |
| 2025-07-29 | BUY | 64 | | | 64.200* | | 61.90 |
| 2025-07-14 | BUY | 128 | | | 65.190* | | 61.72 |
| 2025-06-30 | BUY | 128 | | | 65.250* | | 61.57 |
| 2025-06-25 | BUY | 192 | | | 65.910* | | 61.49 |
| 2025-06-20 | SELL | -32 | | | 65.560* | | 61.40 Profit of 1,965 on sale |
| 2025-06-12 | SELL | -256 | | | 62.120* | | 61.32 Profit of 15,697 on sale |
| 2025-06-02 | BUY | 96 | | | 61.910* | | 61.28 |
| 2025-05-28 | BUY | 64 | | | 57.810* | | 61.35 |
| 2025-05-14 | BUY | 32 | | | 60.370* | | 61.52 |
| 2025-05-13 | BUY | 64 | | | 62.000* | | 61.52 |
| 2025-05-07 | BUY | 96 | | | 70.820* | | 61.32 |
| 2025-04-28 | BUY | 32 | | | 70.750* | | 60.73 |
| 2025-04-16 | BUY | 416 | | | 69.200* | | 60.14 |
| 2025-04-14 | BUY | 64 | | | 68.720* | | 59.97 |
| 2025-04-08 | SELL | -64 | | | 63.050* | | 59.76 Profit of 3,824 on sale |
| 2025-04-04 | SELL | -64 | | | 67.520* | | 59.61 Profit of 3,815 on sale |
| 2025-03-28 | BUY | 320 | | | 67.610* | | 59.27 |
| 2025-03-12 | SELL | -64 | | | 63.260* | | 58.52 Profit of 3,745 on sale |
| 2025-03-04 | SELL | -64 | | | 59.130* | | 58.43 Profit of 3,740 on sale |
| 2025-02-26 | SELL | -128 | | | 55.010* | | 58.48 Profit of 7,485 on sale |
| 2025-02-13 | BUY | 33 | | | 59.190* | | 58.52 |
| 2025-02-12 | BUY | 132 | | | 59.680* | | 58.50 |
| 2025-01-27 | BUY | 32 | | | 60.420* | | 58.30 |
| 2025-01-23 | BUY | 32 | | | 58.690* | | 58.28 |
| 2024-12-09 | BUY | 1,188 | | | 58.030* | | 58.28 |
| 2024-12-04 | BUY | 66 | | | 56.860* | | 58.38 |
| 2024-12-03 | BUY | 99 | | | 56.870* | | 58.41 |
| 2024-11-19 | BUY | 198 | | | 55.690* | | 58.72 |
| 2024-11-18 | BUY | 66 | | | 55.250* | | 58.83 |
| 2024-11-12 | BUY | 128 | | | 61.000* | | 58.76 |
| 2024-11-11 | BUY | 32 | | | 61.740* | | 58.56 |
| 2024-11-11 | BUY | 32 | | | 61.740* | | 58.56 |
| 2024-11-07 | BUY | 160 | | | 58.380* | | 58.36 |
| 2024-11-07 | BUY | 160 | | | 58.380* | | 58.36 |
| 2024-10-23 | BUY | 64 | | | 59.040* | | 59.68 |
| 2024-10-23 | BUY | 64 | | | 59.040* | | 59.68 |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of ANIP
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 41,035 | 0 | 62,694 | 65.5% |
| 2025-09-18 | 72,433 | 15,812 | 127,366 | 56.9% |
| 2025-09-17 | 122,191 | 3,115 | 207,456 | 58.9% |
| 2025-09-16 | 35,757 | 0 | 163,997 | 21.8% |
| 2025-09-15 | 78,192 | 12 | 144,940 | 53.9% |
| 2025-09-12 | 30,941 | 0 | 65,762 | 47.0% |
| 2025-09-11 | 39,419 | 0 | 128,054 | 30.8% |
| 2025-09-10 | 72,168 | 58 | 132,797 | 54.3% |
| 2025-09-09 | 142,073 | 160 | 263,395 | 53.9% |
| 2025-09-08 | 35,490 | 0 | 162,390 | 21.9% |
| 2025-09-05 | 51,458 | 50 | 145,846 | 35.3% |
| 2025-09-04 | 65,824 | 100 | 152,241 | 43.2% |
| 2025-09-03 | 62,176 | 0 | 181,210 | 34.3% |
| 2025-09-02 | 44,473 | 0 | 124,889 | 35.6% |
| 2025-08-29 | 40,674 | 250 | 93,992 | 43.3% |
| 2025-08-28 | 99,168 | 0 | 164,698 | 60.2% |
| 2025-08-27 | 29,327 | 100 | 90,650 | 32.4% |
| 2025-08-26 | 65,777 | 0 | 199,758 | 32.9% |
| 2025-08-25 | 37,903 | 364 | 120,275 | 31.5% |
| 2025-08-22 | 58,262 | 65 | 139,885 | 41.6% |
| 2025-08-21 | 69,041 | 150 | 233,240 | 29.6% |
| 2025-08-20 | 40,298 | 0 | 144,832 | 27.8% |
| 2025-08-19 | 128,579 | 0 | 350,791 | 36.7% |
| 2025-08-18 | 72,497 | 100 | 270,478 | 26.8% |
| 2025-08-15 | 63,290 | 0 | 374,913 | 16.9% |
| 2025-08-14 | 91,445 | 8,700 | 225,232 | 40.6% |
| 2025-08-13 | 105,535 | 4,110 | 254,501 | 41.5% |
| 2025-08-12 | 176,947 | 29,770 | 533,070 | 33.2% |
| 2025-08-11 | 231,265 | 5,230 | 706,298 | 32.7% |
| 2025-08-08 | 294,255 | 16,527 | 803,623 | 36.6% |
| 2025-08-07 | 220,706 | 185 | 397,616 | 55.5% |
| 2025-08-06 | 294,168 | 0 | 430,474 | 68.3% |
| 2025-08-05 | 48,125 | 0 | 71,575 | 67.2% |
| 2025-08-04 | 35,419 | 0 | 53,139 | 66.7% |
| 2025-08-01 | 59,471 | 0 | 92,374 | 64.4% |
| 2025-07-31 | 47,901 | 0 | 84,852 | 56.5% |
| 2025-07-30 | 45,147 | 0 | 95,248 | 47.4% |
| 2025-07-29 | 109,813 | 0 | 199,726 | 55.0% |
| 2025-07-28 | 74,149 | 0 | 114,226 | 64.9% |
| 2025-07-25 | 101,383 | 0 | 158,638 | 63.9% |
| 2025-07-24 | 80,032 | 0 | 117,731 | 68.0% |
| 2025-07-23 | 88,661 | 0 | 122,059 | 72.6% |
| 2025-07-22 | 57,120 | 1,845 | 70,264 | 81.3% |
| 2025-07-21 | 59,264 | 0 | 141,593 | 41.9% |
| 2025-07-18 | 73,816 | 200 | 109,091 | 67.7% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Disclaimer
All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.